SciELO - Scientific Electronic Library Online

 
vol.37 número3Evaluación económica del tratamiento de la trombocitopenia inmune primaria crónica refractaria con agonistas del receptor de la trombopoyetinaAdaptación de la guía farmacoterapéutica de un hospital sociosanitario a pacientes con disfagia índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Farmacia Hospitalaria

versión On-line ISSN 2171-8695versión impresa ISSN 1130-6343

Resumen

GONZALEZ ALVAREZ, A.; GOMEZ BARRERA, M.; BORRAS BLASCO, J.  y  GINER SERRET, E. J.. Analisis of the budget impact of adalimumab and etanercept in rheumatoid arthritis and spondyloarthropathies. Farm Hosp. [online]. 2013, vol.37, n.3, pp.192-197. ISSN 2171-8695.  https://dx.doi.org/10.7399/FH.2013.37.3.581.

Purpose: To assess the economic impact derived from the widening of the administration intervals of adalimumab (ADA) and etanercept (ETN) for the treatment of rheumatoid arthritis (RA) and spondyloarthropathies (SAP) at our working environment. Material and methods: A budget impact model (BIM) was developed to estimate the economic impact that would have widening the usual administration intervals of ADA, 40 mg every 2 weeks and ETN, 50 mg weekly (scenario A), to ADA, 40 mg every 3 weeks, and ETN, 50 mg every 2 weeks (scenario B) according to the guidelines and recommendations applied to these studies, specifying the target population, the study perspective, the temporal horizon, and analysing the study robustness by a threshold univariate sensitivity analysis. Results: 71 patients were included in the study. The application of the BIM showed yearly savings for ADA and ETN of 19.784 € and 38.271 €, respectively. The net cost, that is to say the saving that this would imply within the temporal horizon considered (2 years), was 116.110 €. The sensitivity analysis showed that the estimated BIM for the study period was very robust since the net result in the different scenarios varied very little, being negative in the new scenarios. Conclusions: widening the administration intervals of ADA and ETN to every 3 weeks and 2 weeks respectively, would be a strategy that would allow generating savings in the hospital budget close to 116.110 € for the temporal horizon considered, achieving this way optimization of the treatment with these two drugs.

Palabras clave : Rheumatoid arthritis; Spondyloarthropathies; Budget impact analysis; Adalimumab; Etanercept; Tumour necrosis factor inhibitors.

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons